ACTIVating Resources for the COVID-19 Pandemic: In Vivo Models for Vaccines and Therapeutics.

Document Type

Article

Publication Date

11-11-2020

Keywords

JMG, Animals, Betacoronavirus, Coronavirus, Coronavirus Infections, Cricetinae, Guinea Pigs, Humans, Mice, Pandemics, Pneumonia, Viral, Vaccines

JAX Source

Cell Host Microbe 2020 Nov 11; 28(5):646-659

Volume

28

Issue

5

First Page

646

Last Page

659

ISSN

1934-6069

PMID

33152279

DOI

https://doi.org/10.1016/j.chom.2020.09.016

Abstract

The Preclinical Working Group of Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a public-private partnership spearheaded by the National Institutes of Health, has been charged with identifying, prioritizing, and communicating SARS-CoV-2 preclinical resources. Reviewing SARS-CoV-2 animal model data facilitates standardization and harmonization and informs knowledge gaps and prioritization of limited resources. To date, mouse, hamster, ferret, guinea pig, and non-human primates have been investigated. Several species are permissive for SARS-CoV-2 replication, often exhibiting mild disease with resolution, reflecting most human COVID-19 cases. More severe disease develops in a few models, some associated with advanced age, a risk factor for human disease. This review provides a snapshot that recommends the suitability of models for testing vaccines and therapeutics, which may evolve as our understanding of COVID-19 disease biology improves. COVID-19 is a complex disease, and individual models recapitulate certain aspects of disease; therefore, the coordination and assessment of animal models is imperative.

Link to Full Text

Share

COinS